Abstract
Splenic marginal zone lymphoma (SMZL) is a malignancy of mature B-cells that primarily involves the spleen, but can affect peripheral organs as well. Even though SMZL is overall considered an indolent malignancy, the majority of cases will eventually progress to be more aggressive. In recent years, the gene expression profile of SMZL has been characterized in an effort to identify: 1) the etiology of SMZL, 2) biological consequences of SMZL, and 3) putative therapeutic targets. However, due to the vast heterogeneity of the malignancy, no conclusive target(s) have been deciphered. However, the role of miRNA in SMZL, much as it has in chronic lymphocytic leukemia, may serve as a guiding light. As a result, we review the comprehensive expression profiling in SMZL to-date, as well as describe the miRNA (and potential mechanistic roles) that may play a role in SMZL transformation, particularly within the 7q region.
Highlights
Splenic marginal zone lymphoma (SMZL) is a lowgrade, mature B-cell lymphoma, primarily involving the spleen with variable progression seen in the bone marrow and peripheral blood [1, 2]
CAV1 has been shown to be a crucial piece in immune functioning and dysregulation in malignancies similar to SMZL, and in order to decipher the role of CAV1 on SMZL, in cases of 7q loss of heterozygosity (LOH) or in cases with 7q intact, miRNA regulation should be investigated for their impact
The role of miRNA in cancer is a growing investigative interest, as elucidation of their regulation has proven enlightening for deciphering various malignancies and their progression
Summary
Splenic marginal zone lymphoma (SMZL) is a lowgrade, mature B-cell lymphoma, primarily involving the spleen with variable progression seen in the bone marrow and peripheral blood [1, 2]. As for previously published miRNA data in SMZL, the miR-183 cluster has been shown to be under-expressed when compared to similar B-cell lymphoma samples [76].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
